Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
Clinical trial NCT02557516 · TERMINATED
Trial details
- NCT number
- NCT02557516
- Sponsor
- Innate Pharma
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-09
- Primary completion
- 2018-10-29
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.